Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 1/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-418 SCHEMBL8114587 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL2911067 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL8106821 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL7586948 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL7130413 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL9263504 | 0.95 | CHRNB2 (0.91) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL9260223 | 0.94 | CHRNB2 (0.88) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL8114179 | 0.93 | CHRNB2 (0.86) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14112932 | 0.90 | CHRNB2 (0.81) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL9270411 | 0.88 | CHRNB2 (0.79) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025040605-A1 | OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR FOR TOPICAL ADMINISTRATION TO THE EYE FOR PREVENTING OR TREATING INFLAMMATION OF THE EYE | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2025-02-27 | — | — | WO | claimed |
| CN-119423352-A | Nicotine-substituted compound, water-soluble nicotine-free preparation, preparation method thereof and aerosol system | 深圳梵活生命科学股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-20240173318-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2024-05-30 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023279162-A1 | METHODS OF TREATMENT AND INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2023-01-12 | — | — | WO | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| EP-3713574-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | The Governors of the University of Alberta (CA) | 2020-09-30 | — | — | EP | claimed |
| CN-111629726-A | Method for combatting respiratory depression by activating neuronal heterotopic nicotinic acetylcholine receptors | 阿尔伯塔大学理事会 | 2020-09-04 | — | — | CN | claimed |
| WO-2019100155-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-05-31 | — | — | WO | claimed |
| US-20190054067-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | SAINT JOSEPH'S UNIVERSITY | 2019-02-21 | — | — | US | claimed |
| US-5585111-A | BACKING BEARING ADHESIVE LAYER COMPRISING HOMOGENEOUS MIXTURE OF COPOLYMER CONTAINING ALKYL ACRYLATE OR METHACRYLATE, /S/-3-METHYL-5-/1-METHYL-2-PYRROLIDINYL/ISOXAZOLE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-12-17 | — | — | US | claimed |
| CN-1136773-A | transdermal drug delivery device | MINNESODA MINING AND MANUFACTU (US) | 1996-11-27 | — | — | CN | claimed |
| WO-1996030001-A1 | METHOD OF MAKING A PRESSURE SENSITIVE SKIN ADHESIVE SHEET MATERIAL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| EP-0732922-A1 | TRANSDERMAL DELIVERY DEVICE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| US-5494680-A | Transdermal delivery device | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-02-27 | — | — | US | claimed |
| WO-1995015754-A1 | TRANSDERMAL DELIVERY DEVICE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-06-15 | — | — | WO | claimed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | claimed |
| EP-0588917-A4 | — | — | 1994-04-13 | — | — | EP | claimed |
| EP-0588917-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | claimed |
| WO-1992021339-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173318-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNB4 1806/4885CHRNA3 2020/4885 |
| US-20190054067-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | CHRNA4, CHRNA5, CHRNE | CHRNB2 9/4885CHRNB4 4/4885CHRNA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.